Proton therapy developer Mevion Medical Systems has received 510(k) clearance for its S250 proton therapy system from the U.S. Food and Drug Administration (FDA).
Mevion S250 is designed to preserve all of the treatment benefits of traditional proton therapy systems at a reduced size and complexity, and at a lower cost. This is achieved because the system is powered by a patented TriNiobium Core, according to the company.
Mevion's first proton therapy installation will soon be completed at the Kling Center for Proton Therapy at Barnes Jewish Hospital. Installations are also under way at Robert Wood Johnson University Hospital and at the Stephenson Cancer Center at the University of Oklahoma. Additional sites in Florida and California will follow these installations.
The company said it will deliver and install more than a dozen systems worldwide within the next two years. S250 received CE Mark certification earlier this year.
